Marinosci, AnnalisaAnnalisaMarinosciSculier, DelphineDelphineSculierWandeler, GillesGillesWandelerYerly, SabineSabineYerlyStoeckle, MarcelMarcelStoeckleBernasconi, EnosEnosBernasconiBraun, Dominique LDominique LBraunVernazza, PietroPietroVernazzaCavassini, MatthiasMatthiasCavassiniDecosterd, LaurentLaurentDecosterdGünthard, Huldrych FHuldrych FGünthardSchmid, PatrickPatrickSchmidLimacher, AndreasAndreasLimacher0000-0002-9094-9476Branca, MattiaMattiaBrancaCalmy, AlexandraAlexandraCalmy2024-12-182024-12-182024-11https://boris-portal.unibe.ch/handle/20.500.12422/189678The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.enHIV-1 dual therapydolutegravir + emtricitabinemaintenance treatmentpatient satisfactionquality of life600 - Technology::610 - Medicine & healtharticle10.48620/785583950788510.1093/ofid/ofae618